Solid Biosciences

Solid Biosciences is a biotechnology company focused on developing treatments for Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration. The company generates revenue primarily through research and development collaborations, grants, and potential future product sales. Founded in 2013, Solid Biosciences has faced challenges, including clinical trial setbacks, but remains committed to advancing its lead gene therapy candidate, SGT-001. The company aims to address the unmet medical needs of DMD patients by leveraging its expertise in gene therapy, disease biology, and drug development.

Recent Posts by Solid Biosciences

1-11 of 11